title: Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.
abstract: These NCCN Guidelines Insights highlight the important updates/changes specific to the management of metastatic breast cancer in the 2012 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer. These changes/updates include the issue of retesting of biomarkers (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2) on recurrent disease, new information regarding first-line combination endocrine therapy for metastatic disease, a new section on monitoring of patients with metastatic disease, and new information on endocrine therapy combined with an mTOR inhibitor as a subsequent therapeutic option.
authors: Stanford Cancer Institute, CA, USA.
authors: Robert W
authors: RW
authors: Carlson
authors: D Craig
authors: DC
authors: Allred
authors: Benjamin O
authors: BO
authors: Anderson
authors: Harold J
authors: HJ
authors: Burstein
authors: Stephen B
authors: SB
authors: Edge
authors: William B
authors: WB
authors: Farrar
authors: Andres
authors: A
authors: Forero
authors: Sharon Hermes
authors: SH
authors: Giordano
authors: Lori J
authors: LJ
authors: Goldstein
authors: William J
authors: WJ
authors: Gradishar
authors: Daniel F
authors: DF
authors: Hayes
authors: Clifford A
authors: CA
authors: Hudis
authors: Steven Jay
authors: SJ
authors: Isakoff
authors: Britt-Marie E
authors: BM
authors: Ljung
authors: David A
authors: DA
authors: Mankoff
authors: P Kelly
authors: PK
authors: Marcom
authors: Ingrid A
authors: IA
authors: Mayer
authors: Beryl
authors: B
authors: McCormick
authors: Lori J
authors: LJ
authors: Pierce
authors: Elizabeth C
authors: EC
authors: Reed
authors: Mary Lou
authors: ML
authors: Smith
authors: Hatem
authors: H
authors: Soliman
authors: George
authors: G
authors: Somlo
authors: Richard L
authors: RL
authors: Theriault
authors: John H
authors: JH
authors: Ward
authors: Antonio C
authors: AC
authors: Wolff
authors: Richard
authors: R
authors: Zellars
authors: Rashmi
authors: R
authors: Kumar
authors: Dorothy A
authors: DA
authors: Shead
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D047428:Protein Kinase Inhibitors; D058570:TOR Serine-Threonine Kinases